Not yet recruitingPhase 3

Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth

Lead sponsor

Children's Hospital Los Angeles

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

150

Study population

Bariatric Surgery, Obesity / overweight

Eligibility highlights

Primary endpoint

•Percent Body Mass Index

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06934655

Org study IDAPP-IP

Timeline

Milestones

Study first posted2025-04-18actual

Last update posted2026-03-17actual

Study start2026-06-01estimated

Primary completion2030-11-01estimated

Study completion2033-11-01estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Bariatric SurgeryObesity / overweight

Who can enroll

Minimum age12 Years

Maximum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•ages 12 to 18 years

•Tanner stage 3 or higher

•severe obesity (defined as a BMI greater than 35 kg/m2 or BMI ≥140% of the 95th percentile)

•currently undergoing primary surgical weight loss through the pediatric bariatric surgery pathway at Children's Hospital Los Angeles

•be willing to have blood collected before and after surgical procedure at defined points

•be willing to have clinical data entered into a prospective database; 8) presence of a consenting caregiver

•be taking semaglutide 2.4 mg weekly as part of their routine medical care prior to surgery as part of their obesity treatment program, apart from any planned surgical procedure.

Exclusion criteria

•have a previous diagnosis of type 1 diabetes

•taking any medications known to influence body composition or prevent weight loss or promote weight gain (e.g. prednisone)

•have been diagnosed with syndromes or diseases that may influence the postoperative course (e.g., Cushing syndrome, Down syndrome, Prader Willi Syndrome)

•have significant comorbid medical conditions necessitating frequent hospitalization that may require interruption of medications and/or that would make early re-initiation of semaglutide unsafe due to the other medical comorbidities

•refuse to comply with eligibility criteria.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Other clinical outcomes

Weight & body composition

1 endpoint

Primary/protocol endpoint

Percent Body Mass Index

Time frame:From enrollment to the end of the end of the study at 24 months

descriptive, improvement

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint

Modified percent time in range

Time frame:From enrollment to the end of the study period at 24 months

CGM time-in-range

percent change from baseline, improvement

Other clinical outcomes

1 endpoint

Other/protocol endpoint

Eating in the absence of hunger

Time frame:Month 24 compared to baseline

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.